β-Elemene

β-Elemene is a naturally occurring sesquiterpene compound extracted primarily from Curcuma wenyujin and other Zingiberaceae plants. It exerts anticancer activity by inducing mitochondrial-mediated apoptosis, inhibiting tumor cell proliferation, and modulating cell cycle arrest at the G2/M phase.

Origin & History

β-Elemene is a sesquiterpene extracted from the rhizome of Curcuma wenyujin, a plant in the ginger family. It is produced through distillation or solvent extraction, yielding a volatile oil component used in pharmaceutical formulations in China.

Historical & Cultural Context

β-Elemene is derived from Curcuma wenyujin, used in traditional Chinese medicine for various ailments. Its inclusion in modern cancer therapy reflects its historical use as a medicinal agent.

Health Benefits

• Enhances clinical efficacy in non-small cell lung cancer when combined with chemotherapy, as shown in a meta-analysis of 15 RCTs involving 1,410 patients.
• Improves response rates in acute myeloid leukemia, achieving an 80.8% effective rate in a study of 120 patients.
• Increases overall efficacy in controlling malignant pleural effusion, demonstrated in a pooled analysis of 46 trials with 2,992 patients.
• Promotes apoptosis and impairs glucose metabolism in cancer cells, based on in vitro studies.
• Downregulates cancer stem cell markers, enhancing chemotherapy sensitivity, as seen in preclinical studies.

How It Works

β-Elemene triggers intrinsic apoptosis by downregulating Bcl-2 and upregulating Bax, disrupting mitochondrial membrane potential and activating caspase-3 and caspase-9 cascades. It inhibits tumor proliferation by suppressing cyclin B1 and CDK1 expression, causing G2/M phase cell cycle arrest. Additionally, β-Elemene inhibits the PI3K/Akt/mTOR and MAPK/ERK signaling pathways, reducing cancer cell survival, migration, and angiogenesis mediated through VEGF suppression.

Scientific Research

Clinical evidence primarily comes from randomized controlled trials conducted in China, with varying methodological quality. A 2019 meta-analysis (PMID: Not Available) of 15 trials confirmed its efficacy in lung cancer. Further research highlights its potential in acute myeloid leukemia and malignant pleural effusion.

Clinical Summary

A meta-analysis of 15 randomized controlled trials involving 1,410 patients demonstrated that β-Elemene combined with chemotherapy significantly enhances clinical efficacy in non-small cell lung cancer, improving tumor response rates and quality of life compared to chemotherapy alone. In a clinical study of 120 acute myeloid leukemia patients, β-Elemene injection achieved an effective rate of 80.8%, outperforming standard treatment arms. Evidence is primarily derived from Chinese clinical trials, which often vary in blinding quality and reporting standards, warranting cautious interpretation. Overall, the body of evidence supports adjunctive use in oncology settings, but large-scale, internationally registered phase III trials are still needed to confirm findings.

Nutritional Profile

β-Elemene is not a nutrient or food substance but a sesquiterpene bioactive compound (molecular formula: C₁₅H₂₄; molecular weight: 204.35 g/mol) extracted primarily from the rhizome of Curcuma wenyujin (温郁金), a traditional Chinese medicinal plant related to turmeric. It is classified as a terpene hydrocarbon and is administered pharmaceutically rather than consumed as part of a diet. Key details: • **Chemical class:** Sesquiterpene (1-methyl-1-vinyl-2,4-diisopropenylcyclohexane); exists as one of three isomers (α-, β-, γ-elemene), with β-elemene being the most pharmacologically studied. • **Natural source concentration:** Present in Curcuma wenyujin essential oil at approximately 3–8% of total volatile oil content; also found in smaller quantities in Curcuma zedoaria, celery seed oil, and certain citrus peel oils. • **Pharmaceutical formulations:** Available as β-Elemene Injection (elemene emulsion injection, typically 20 mg/mL) and oral emulsion in Chinese clinical settings (approved by CFDA). Typical clinical doses range from 400–800 mg/day intravenously or 1,200–1,600 mg/day orally. • **Macronutrients/Micronutrients:** Not applicable — β-elemene contains no proteins, carbohydrates, fats, vitamins, minerals, or dietary fiber. It is a pure lipophilic hydrocarbon compound with zero caloric/nutritional contribution. • **Bioavailability notes:** β-Elemene is highly lipophilic (logP ~4.6) with poor aqueous solubility, necessitating emulsion-based delivery systems for clinical use. Oral bioavailability is relatively low due to extensive first-pass hepatic metabolism; injectable emulsion formulations significantly improve systemic bioavailability. It undergoes hepatic cytochrome P450-mediated oxidative metabolism. The compound crosses the blood-brain barrier to some extent, which has been explored in glioma research. • **Key bioactive properties (non-nutritional):** Functions primarily as an antineoplastic agent via multiple mechanisms including cell cycle arrest (G2/M phase), induction of apoptosis, inhibition of angiogenesis, reversal of multidrug resistance (downregulation of P-glycoprotein), and immunomodulation (enhancement of T-cell and NK-cell activity). It is not considered a dietary supplement or nutritional compound.

Preparation & Dosage

In vivo studies used 5 mg/kg intraperitoneally daily for seven days in lung cancer models. In vitro effects begin at 5 μg/mL. Dosage in clinical practice is typically via elemene injections. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Curcumin, Cisplatin, Oxaliplatin, Homoharringtonine, Arabinosylcytosine

Safety & Interactions

β-Elemene is generally well tolerated when administered as a clinical injection formulation, with the most commonly reported adverse effects including mild phlebitis, fever, and gastrointestinal symptoms such as nausea and vomiting. Hypersensitivity reactions have been reported with intravenous β-Elemene emulsion preparations, and premedication protocols are sometimes employed in clinical settings. Potential pharmacokinetic interactions exist with chemotherapy agents metabolized via CYP450 enzymes, though specific interaction data remain limited. β-Elemene is not recommended during pregnancy or lactation due to insufficient safety data, and patients on anticoagulants or immunosuppressants should consult a physician before use.